Vosoritide
A modified C-type natriuretic peptide analog developed by BioMarin Pharmaceutical, FDA-approved as Voxzogo for children with achondroplasia. The first targeted pharmacological treatment for the most common form of genetic short stature.
What is Vosoritide?
Vosoritide is a 39-amino-acid modified analog of human C-type natriuretic peptide (CNP), developed by BioMarin Pharmaceutical and marketed as Voxzogo for the treatment of achondroplasia in children with open growth plates. Achondroplasia is the most common form of disproportionate short stature, caused by a gain-of-function mutation in FGFR3 (fibroblast growth factor receptor 3) that over-represses endochondral bone growth at the growth plate. Vosoritide was designed to counteract this over-active FGFR3 signaling by engaging NPR-B (natriuretic peptide receptor B) on growth-plate chondrocytes, reactivating the natural cartilage-to-bone elongation pathway. The FDA approved Voxzogo in November 2021 for children with achondroplasia aged 5 years and older with open epiphyses, and expanded the indication on October 20, 2023 to children of all ages with open growth plates (the US label sets no minimum age) — making it the first targeted therapy approved for this condition (growth hormone has been used for achondroplasia in Japan since 1997). Families researching vosoritide are typically parents of a child recently diagnosed with achondroplasia weighing a difficult treatment decision. The evidence base is strong by rare-disease standards, and the growth-velocity benefit is real — but the absolute magnitude is modest relative to the difference in adult stature between achondroplasia and average-stature individuals, and long-term outcomes on adult height, cardiovascular, neurological, and orthopedic complications of achondroplasia are still being studied.
What Vosoritide Is Investigated For
Vosoritide is investigated and FDA-approved for achondroplasia in children with open growth plates — the first targeted therapy approved for this condition, initially approved November 2021 for children aged 5 and older and expanded in October 2023 to all ages with open growth plates in the US (4 months and older in the EU); a second CNP-pathway drug, once-weekly navepegritide (YUVIWEL), received US accelerated approval in February 2026 for children 2 and older. The strongest evidence is the pivotal Phase 3 trial (Savarirayan et al., Lancet 2020) in 121 children showing approximately 1.57 cm/year increase in annualized growth velocity versus placebo, supported by open-label extension data showing sustained benefit across several years of continued daily dosing. The mechanism is unusually clean: vosoritide's NPR-B–cGMP pathway activation directly antagonizes the over-active FGFR3-MAPK signaling that causes achondroplasia. The honest caveats are important for families weighing treatment. Vosoritide is not a cure — it does not correct the underlying FGFR3 mutation and the growth-velocity benefit, while statistically significant, is modest relative to the roughly 35 to 45 cm adult height gap between achondroplasia (average adult height about 131 cm in men and 124 cm in women) and average-stature peers. Final adult height data have not yet been published for any treated group (BioMarin's application for full approval, which includes adult-height data, is under FDA review with a target action date of February 28, 2027), effects on non-stature complications (spinal stenosis, foramen magnum stenosis, sleep apnea) remain emerging rather than established, and the decision to treat carries real values considerations within the achondroplasia community.
History & Discovery
The scientific path to vosoritide began with recognition in the 1990s and 2000s that FGFR3 gain-of-function mutations cause achondroplasia and that C-type natriuretic peptide (CNP) signaling, acting through NPR-B and cGMP, is a major positive regulator of endochondral bone growth that opposes FGFR3-MAPK activity. Mouse-genetic work showed that overexpressing CNP in chondrocytes could rescue the achondroplasia phenotype in Fgfr3-mutant animals — a striking proof-of-concept that framed the therapeutic opportunity. Native CNP has a short plasma half-life because neutral endopeptidase (neprilysin) rapidly clears it, making it impractical as a systemic therapeutic. BioMarin Pharmaceutical engineered a modified analog (BMN-111) with an N-terminal extension that resists neprilysin cleavage while preserving NPR-B agonism. BMN-111 advanced through Phase 1 healthy-volunteer studies, a Phase 2 dose-escalation program in children with achondroplasia, and culminated in the pivotal Phase 3 trial (Savarirayan et al., Lancet 2020) that demonstrated the ~1.57 cm/year growth velocity improvement versus placebo over 52 weeks. FDA approved Voxzogo on November 19, 2021 for children with achondroplasia aged 5 and older with open epiphyses — the first targeted therapy approved in the US for this condition. In October 2023 the FDA expanded the indication to children of all ages with open growth plates, based on a randomized placebo-controlled trial in children under 5 plus pharmacokinetic data. The EU actually authorised Voxzogo first, on 26 August 2021, for children aged 2 and older (extended to 4 months and older in late 2023). Japan approved it in 2022 for children from birth, and other regulators followed with differing age criteria. The relationship with the achondroplasia community has been contested rather than collaborative. Little People of America issued a position statement after approval arguing that the challenges associated with short stature are primarily a matter of inaccessible architecture, an absence of universal design, and societal intolerance, that the drug does not address the health and quality-of-life problems that matter most to people with dwarfism, and that it is not yet known whether a gain in growth velocity translates into more meaningful outcomes. A 2026 paper in the American Journal of Bioethics likewise lists inclusion of disability communities in the research process as an unmet requirement rather than an achievement, alongside long-term psychosocial follow-up and mandated data sharing. Roughly four in five babies with achondroplasia are born to average-stature parents, so the treatment decision usually falls to families with no prior contact with the dwarfism community — a context clinicians and families continue to navigate case by case.
How It Works
Children with achondroplasia have a genetic change in a protein called FGFR3 that makes it too active. Overactive FGFR3 tells the cartilage cells at the growth plates of a child's bones to slow down — which is why achondroplasia causes shorter limbs and shorter overall stature. Vosoritide is a lab-made version of a natural signal called CNP that does the opposite: it tells those same cartilage cells to keep growing normally. By partially counterbalancing the overactive FGFR3 signal, vosoritide helps bones grow longer during childhood, as long as growth plates are still open.
Vosoritide is a modified 39-amino-acid analog of human C-type natriuretic peptide (CNP), the physiological ligand for natriuretic peptide receptor B (NPR-B, also known as NPR2). Native 22-residue CNP is cleared within minutes by neutral endopeptidase (neprilysin). Vosoritide is the 37 C-terminal amino acids of human CNP-53 plus an added Pro-Gly at the N-terminus, which confers neprilysin resistance, and it is manufactured recombinantly in Escherichia coli. Its plasma half-life is still short — about 21 to 28 minutes in children — but NPR-B activation, measured as urinary cGMP, peaks about 2 hours after a dose, supporting once-daily injection. Achondroplasia is caused by a recurrent gain-of-function mutation in FGFR3 (most commonly G380R), which constitutively activates downstream MAPK (RAS/RAF/MEK/ERK) signaling in growth-plate chondrocytes. Over-active MAPK suppresses chondrocyte proliferation, differentiation, and hypertrophy, blunting endochondral ossification — the process by which long bones lengthen at the growth plate during childhood. NPR-B activation by vosoritide triggers guanylyl-cyclase-mediated cGMP production in the same chondrocytes. cGMP inhibits the RAF–MEK–ERK axis downstream of FGFR3, and the label pins the point of interference specifically to RAF-1, effectively antagonizing the over-active FGFR3 signal at the MAPK node. This also explains why a CNP analogue can only ever be a partial counter: FGFR3 signals through STAT1 as well as the MAPK cascade, and vosoritide touches only the latter. The result is partial restoration of chondrocyte proliferation and differentiation, longer resting and proliferative zones at the growth plate, and increased linear bone growth. The effect is limited to children with open growth plates; once epiphyseal closure occurs, NPR-B-driven chondrocyte signaling is no longer available as a therapeutic lever. A frequent question is whether the extra growth is proportionate or simply lengthens the legs. At 52 weeks the pivotal trial found no difference: the upper-to-lower body segment ratio changed by −0.01 against placebo (95% CI −0.05 to 0.02, p=0.5), and infigratinib's Phase 3 trial found much the same. Longer follow-up is more favourable but less rigorous — the Phase 3 extension reported a significant improvement in that ratio at three years for younger children against population-level untreated controls rather than a randomized comparator, while the arm-span-to-height ratio stayed consistent with untreated participants. Real-world cohorts split: proportions were unchanged in Brazilian and Latin American series, improved in a Chinese cohort and in a pooled pre-post synthesis. The defensible summary is that vosoritide does not appear to worsen proportions and may modestly improve them over years, but nothing at 52 weeks supports a proportion claim.
Evidence Snapshot
Human Clinical Evidence
Strong by rare-disease standards. The pivotal Phase 3 randomized, placebo-controlled trial (Savarirayan et al., Lancet 2020) in 121 children aged 5–14 with achondroplasia showed a mean increase in annualized growth velocity of approximately 1.57 cm/year versus placebo at 52 weeks, supporting FDA approval in November 2021. The 2023 expansion rested on a randomized, placebo-controlled Phase 2 trial in children aged 3 to 59 months plus matching drug-exposure data from older children. Of 75 children recruited, 11 were assigned as open-label sentinels and 64 were randomized, 32 to vosoritide and 32 to placebo; the height Z-score gain versus placebo was 0.25, with a 95% confidence interval (−0.02 to 0.53) that just crossed zero. One child in the vosoritide arm died during that trial, with sudden infant death syndrome and respiratory syncytial virus bronchiolitis among the serious adverse events recorded in the treated group; no causal link to vosoritide was established, and the much larger Phase 3 extension has recorded no deaths across 464 person-years. Extension data now cover up to 6 years of continuous treatment with no long-term harms seen, and a 2026 Phase 3 trial in hypochondroplasia (n=81) showed +2.33 cm/year over placebo. Post-marketing registries and long-term follow-up are ongoing.
Animal / Preclinical
Strong. CNP-NPR-B biology and its antagonism of FGFR3-MAPK signaling is well characterized in mouse models of achondroplasia, including the classic Fgfr3-knockin models where CNP analogs rescue growth-plate architecture and bone length.
Mechanistic Rationale
Very strong and specific. The molecular mismatch in achondroplasia (over-active FGFR3-MAPK in chondrocytes) is directly counteracted by NPR-B-driven cGMP inhibition of the same MAPK pathway — a mechanistically clean match.
Research Gaps & Open Questions
What the current literature has not yet settled about Vosoritide:
- 01Final adult height outcomes for children starting treatment in infancy under the 2023 indication expansion — those children have not yet completed growth.
- 02Effect on non-stature complications of achondroplasia (foramen magnum stenosis, spinal stenosis, sleep apnea, otitis media) — a 2026 pooled analysis of 230 trial participants found complication prevalence consistent with or lower than untreated natural-history rates, but this is observational and not yet confirmed in controlled long-term data.
- 03Optimal duration of therapy and optimal age to start — whether treating from earliest infancy yields proportionally greater adult-height gain than starting at age 5 is a key empirical question still accumulating data, and at least two real-world analyses point toward greater effect with later rather than earlier initiation.
- 04Whether first-year response predicts anything — a 24-month real-world cohort found that height-velocity gain over the first 12 months did not significantly predict height-SDS gain at 24 months, which undercuts the intuitive practice of judging response at one year.
- 05Indications beyond skeletal dysplasia — vosoritide is now in trials for mucopolysaccharidosis IVA and VI and in a dedicated trial for hypochondroplasia in children under 36 months, neither of which has reported.
- 06Head-to-head comparisons — there are none yet against once-weekly navepegritide (YUVIWEL, US accelerated approval February 2026; +1.49 cm/year over placebo) or oral infigratinib, an FGFR1-3 tyrosine kinase inhibitor (+1.74 cm/year in Phase 3 PROPEL 3), and the trials enrolled different age ranges. BioMarin's ASPEN trial is testing its weekly long-acting CNP, BMN 333, directly against vosoritide.
- 07Benefit and risk in other growth disorders — vosoritide is being tested in hypochondroplasia (positive Phase 3), idiopathic short stature, Noonan syndrome, and Turner syndrome, and in investigator-led trials some children with Turner syndrome, ACAN, or RASopathy variants developed slipped capital femoral epiphysis or knock-knees, so the balance may differ by condition.
- 08Quality-of-life and functional outcomes — growth velocity is the regulatory endpoint, but what matters to families is broader (function, complications, psychosocial outcomes); validated outcome measures in this domain are still maturing.
- 09Safety signals at long exposures and in larger populations — post-marketing surveillance will continue to characterize rare adverse events and long-term outcomes.
Forms & Administration
Voxzogo is supplied as a lyophilized powder for reconstitution into a small-volume subcutaneous injection, dosed once daily based on body weight (approximately 15 mcg/kg, with a weight-based dose table in the label). Injection is performed at home by a caregiver, typically in the upper arm, thigh, abdomen, or buttock, after training by the prescribing specialist and specialty pharmacy. All injectable peptides in children should only be administered under the guidance of a qualified healthcare provider; injection technique, dose preparation, and adverse-event monitoring are taught and reinforced through the Voxzogo patient support program.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Once-daily subcutaneous injection dosed by the label's weight bands, which set the dose, injection volume, and vial strength (0.4, 0.56, or 1.2 mg) from 3 kg upward — for example 0.096 mg at 3 kg, 0.24 mg at 8 to 11 kg, 0.4 mg at 22 to 32 kg, and 0.8 mg at 90 kg or more. In children 2 and older this works out to roughly 15 mcg/kg; under-2s in the infant trial received 30 mcg/kg, switching to 15 mcg/kg at their second birthday. The Phase 3 trial used 15 mcg/kg as the selected dose following the Phase 2 dose-escalation program. Dose is adjusted upward over time as the child grows.
Frequency
Once daily, administered at a consistent time of day chosen by the family and clinician. The label asks for the injection at about the same time each day, after adequate food and about 240 to 300 mL (8 to 10 oz) of fluid in the hour before — the food and fluid are there to reduce the risk of a blood-pressure drop, not to help adherence. A missed dose can be given within 12 hours; after that, skip it and resume the next day.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous daily therapy throughout childhood and adolescence while growth plates remain open. Therapy is not intended to continue after growth plates close, because NPR-B-driven chondrocyte activity is no longer a therapeutic target at that point. The label directs that treatment be permanently discontinued once closure of the epiphyses confirms there is no further growth potential, with growth monitored every 3 to 6 months to establish when that point has been reached. The optimal age to start treatment (and whether starting in infancy vs. later childhood meaningfully changes adult height outcomes) is still being studied in post-marketing follow-up.
Protocol Notes
Voxzogo is distributed through a manufacturer-managed specialty pharmacy network and requires specialist prescription — typically from a pediatric endocrinologist, clinical geneticist, or skeletal-dysplasia specialist. Families typically reconstitute the lyophilized product and administer a small-volume subcutaneous injection using an insulin-style syringe, after training by the prescribing team. Injection sites (back of the upper arm, front of the thigh, lower abdomen at least 5 cm from the navel, top of the buttock) should rotate, and the label says not to use the same area two days in a row. Vials can be kept at room temperature for up to 90 days but never returned to the fridge, and a reconstituted dose must be given within 3 hours. Because CNP-family peptides transiently lower blood pressure, the label asks for adequate food intake and about 240 to 300 mL of fluid in the hour before each dose; most children tolerate this without symptomatic hypotension. In the pivotal trial 8 of 60 children on vosoritide (13%) had a transient fall in blood pressure versus 3 of 61 on placebo (5%), with a median onset 31 minutes after injection and resolution within a median of 31 minutes, and 2 of 60 had a symptomatic episode with vomiting or dizziness versus none on placebo. The very short half-life is part of why that risk stays manageable: it confines the vasorelaxant effect to roughly a half-hour window rather than spreading it across the day. The pharmacodynamic effect outlasts the drug by far — urinary cGMP peaks about 2 hours after a dose and the collagen marker CXM stays elevated beyond 24 months — which is what makes once-daily dosing of a minutes-long peptide coherent. The 15 mcg/kg dose was chosen because urinary cGMP response is near saturation there, so higher doses buy little additional activity. The decision to initiate vosoritide is not purely medical — it involves values and priorities that differ across families and within the achondroplasia community. Families considering treatment benefit from consultation with a skeletal-dysplasia specialist, time to discuss expected growth-velocity benefit versus injection burden and unknowns, and, for many, engagement with patient-advocacy organizations such as Little People of America.
All dosing, initiation, and monitoring decisions for a child with achondroplasia should be made by a qualified pediatric specialist. The numbers above describe the FDA-labeled approach; individual dosing and continuation decisions require medical evaluation.
Timeline of Effects
Onset
A measurable increase in annualized growth velocity typically emerges within the first 6 months of daily dosing, with the pivotal Phase 3 trial's primary endpoint assessed at 52 weeks. Subjective signs of effect in individual children are not reliable; growth velocity is a statistical quantity that requires months of height measurement.
Peak Effect
Growth-velocity benefit in published data persists across the years of continued daily dosing while growth plates remain open. In the Phase 3 extension (119 children, up to 6 years of treatment), growth velocity on vosoritide stayed close to that of average-stature children before puberty, running about 1.84 cm/year above untreated children in boys and 1.44 cm/year in girls across integer ages 6 to 16 and adding an estimated 5.75 cm over three years against an external untreated cohort. The cumulative effect on adult height depends on years of treatment, which is the usual argument for starting early and continuing through adolescence — but the real-world evidence is not settled in that direction. A single-centre analysis of children transitioning from growth hormone found greater benefit when vosoritide was started at age 4 or later, and a Brazilian cohort found a significant interaction between age and treatment effect. Whether starting in infancy yields proportionally more adult height than starting at 5 remains an open empirical question rather than an established principle.
After Discontinuation
Growth velocity returns to the pre-treatment achondroplasia trajectory after discontinuation; vosoritide has not been shown to confer lasting growth benefit after stopping. There is no mechanism by which NPR-B-driven chondrocyte activity would persist after the peptide is cleared, and vosoritide's plasma half-life is only about 21 to 28 minutes, with a median time to peak concentration of 15 minutes.
Common Questions
Is vosoritide approved for hypochondroplasia?
Not yet. Hypochondroplasia is a milder FGFR3-related condition. In the Phase 3 CANOPY-HCH-3 trial, 81 children aged 3 to under 18 were randomized to daily vosoritide or placebo for a year, and vosoritide added 2.33 cm/year of growth velocity over placebo, with no serious (grade 3 or higher) side effects and no discontinuations for side effects. BioMarin submitted a US application in 2026 and has said a launch could come in 2027. Until then, any use in hypochondroplasia is off-label.
How does vosoritide compare with YUVIWEL (navepegritide) and infigratinib?
All three aim at the same overactive FGFR3 signal. Navepegritide works through the same receptor as vosoritide but is injected once a week; it received US accelerated approval in February 2026 for children 2 and older and added 1.49 cm/year over placebo in its pivotal APPROACH trial — which was a phase 2b study, not a phase 3, so it sits a step below the other two readouts in trial hierarchy even though its effect size is directly comparable. Infigratinib is a once-daily oral pill — a tyrosine kinase inhibitor acting across FGFR1 to FGFR3 rather than on FGFR3 alone — and added 1.74 cm/year over placebo in its Phase 3 trial. It is not approved for achondroplasia; the only infigratinib product on the US market is for adult cholangiocarcinoma. No trial has compared any of these directly with vosoritide's 1.57 cm/year, and the trials enrolled different age ranges, so ranking them is not yet possible.
Does vosoritide make children taller as adults?
That has not yet been shown. The FDA approval is an accelerated approval based on growth velocity, with continued approval contingent on confirmatory trials verifying clinical benefit. BioMarin has now filed long-term data, including adult height, to convert to full approval, with an FDA target decision date of February 28, 2027, and Health Canada likewise made its 2026 approval conditional on a final-adult-height study.
How much does vosoritide actually increase a child's height?
The pivotal Phase 3 trial (Savarirayan et al., Lancet 2020) showed an average increase of approximately 1.57 cm per year in annualized growth velocity versus placebo in children aged 5–14. This is a real, statistically significant effect, but it is helpful to have honest context: average adult height in achondroplasia — reported across countries as roughly 127 to 135 cm for men and 120 to 126 cm for women — is roughly 35 to 45 cm shorter than average-stature peers, so accumulating the trial's annual velocity gain across years of open growth plates produces meaningful but partial catch-up. Longer-term data are more informative than the one-year figure: in the Phase 3 extension, children treated for three years had an estimated 5.75 cm of additional height compared with untreated children from a natural-history cohort — an external comparison, not a randomized one. Whether starting in infancy substantially changes adult height is still being studied.
Does vosoritide prevent the surgeries and the sleep apnoea?
This is the question the dwarfism community itself has pressed hardest, and it is genuinely unresolved because no trial was powered on it. The most favourable evidence is a pooled analysis of 230 participants across six trials reporting foramen magnum decompression in 3.0% overall, with complication prevalence consistent with or lower than untreated natural-history rates. Against that, a 2026 case series found that three of five infants treated early still progressed to high-grade foramen magnum stenosis and underwent decompression between 8 and 18 months of age, and that the abnormal pattern of cranial base closure did not normalise. On sleep apnoea, a 49-child retrospective study found a median apnoea-hypopnoea index of 3.2 events per hour on vosoritide versus 6.9 off it, but the difference was not statistically significant (p=0.105) and the authors state the study cannot establish a respiratory effect. The honest answer is that nobody yet knows.
What happens if a dose is missed or accidentally doubled?
A missed dose can be given within 12 hours of the usual time; after that the label says to skip it and resume the next day. On overdose there is one published case: a three-month-old inadvertently received a double dose of 0.24 mg, about 53 micrograms per kilogram, during home self-injection and remained completely asymptomatic, with no hypotension, lethargy or pallor. That is a single case and not a safety assurance, but it is reassuring for the specific fear most caregivers have about home administration, where the dose is drawn up by hand and there is no auto-injector.
Does the extra growth change body proportions, or just make the legs longer?
At one year, neither — it simply adds height without measurably changing proportions. The pivotal trial measured the upper-to-lower body segment ratio and found a difference of −0.01 against placebo (95% CI −0.05 to 0.02, p=0.5), and infigratinib's Phase 3 trial found much the same. Over three years the Phase 3 extension did report a significant improvement in that ratio for younger children, but against population-level untreated controls rather than a randomized comparator, and arm-span-to-height ratio remained consistent with untreated participants. Real-world cohorts disagree with each other: unchanged in Brazilian and Latin American series, improved in a Chinese cohort. The defensible reading is that vosoritide does not appear to worsen proportions and may modestly improve them with years of treatment, but no proportion claim is supported at 52 weeks.
Is vosoritide a cure for achondroplasia?
No. Vosoritide does not correct the underlying FGFR3 mutation and does not prevent all the medical complications associated with achondroplasia — which can include spinal stenosis, foramen magnum stenosis, sleep apnea, and orthopedic issues. It specifically targets the growth-plate biology that produces short stature, by reactivating endochondral bone elongation. Whether it meaningfully reduces the incidence or severity of non-stature complications is being studied but not fully established.
How is vosoritide given, and by whom?
Vosoritide is administered as a once-daily subcutaneous injection, weight-based (approximately 15 mcg/kg in the pivotal trial, with a dose table in the Voxzogo label). It is typically given at home by caregivers by dissolving a single-dose vial of powder with the supplied prefilled diluent syringe and injecting with a small administration syringe (there is no auto-injector), after training by the prescribing clinician and specialty pharmacy team. Decisions about initiating, continuing, or pausing therapy should involve a pediatric endocrinologist, geneticist, or other specialist familiar with achondroplasia — the Little People of America medical advisory board and academic skeletal-dysplasia clinics are common points of contact for families navigating the decision.
Who Vosoritide Is NOT For
- •Growth plates closed (epiphyseal fusion) — vosoritide has no activity once chondrocyte proliferation at the growth plate has ceased.
- •Known hypersensitivity to vosoritide or any excipient in the Voxzogo formulation. (The US label itself lists no formal contraindications; the items here are practical limits.)
- •Children with conditions that predispose to symptomatic hypotension, where CNP-family vasorelaxant activity could be clinically meaningful — including significant cardiovascular disease or concurrent use of agents that substantially lower blood pressure.
- •Age limits differ by country — the US label has no minimum age, while the EU and Canadian labels start at 4 months; evidence in children under 5 rests on a smaller randomized trial, so the youngest infants have the least follow-up.
- •Reduced kidney function (eGFR below 60 mL/min/1.73 m²) — the label does not recommend use because it has not been studied.
- •Pregnancy and breastfeeding — vosoritide is a pediatric therapy; these states are not clinically relevant to the approved population but remain outside the approval envelope.
Drug & Supplement Interactions
Formal drug-interaction studies for vosoritide are limited because the target population is pediatric and most children with achondroplasia are not on extensive concomitant medications. The label says it is broken down by catabolic pathways into small peptide fragments and amino acids; in laboratory studies it neither inhibits nor induces CYP450 enzymes, and it is unlikely to inhibit the major uptake and efflux transporters (OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp, BSEP). No clinical interaction studies have been done. At the maximum approved dose vosoritide does not prolong the QT interval to any clinically relevant extent. The main theoretical interaction concern is additive blood-pressure-lowering with other agents that reduce blood pressure. Because CNP-family peptides have vasorelaxant activity via NPR-B-driven cGMP, concurrent antihypertensive medications, nitrates, phosphodiesterase-5 inhibitors, or other vasodilators could compound transient reductions in blood pressure. In the pediatric achondroplasia population this is rarely clinically relevant, but the label notes that children with significant heart or vascular disease and those on blood-pressure medicines were excluded from the trials and the Voxzogo dosing strategy (administered with a meal or snack, ensuring adequate hydration) is designed to minimize the risk of symptomatic hypotension. Families should disclose all concomitant medications, over-the-counter products, and supplements to the prescribing specialist and to the specialty pharmacy managing dispensation.
Safety Profile
Common Side Effects
Cautions
- • Approved only for children with achondroplasia who have open epiphyses — use stops once growth plates close
- • Not approved for adults; efficacy has only been studied in children
- • Not recommended for children with reduced kidney function (eGFR below 60 mL/min/1.73 m²); the effect of kidney or liver impairment has not been studied
- • Slipped capital femoral epiphysis (a slip at the hip growth plate) has been reported in investigator-led vosoritide trials in other short-stature conditions — 2 of 5 girls with Turner syndrome, 2 of 12 children with ACAN variants and 1 of 11 with a RASopathy, but none of the 7 with NPR2 variants and none of 24 with hypochondroplasia. All five cases occurred after more than 12 months of treatment and all were the rare valgus type. It is not a labeled risk in achondroplasia, but new hip or knee pain or a limp after the first year of treatment deserves prompt evaluation
- • CNP-family peptides can lower blood pressure; caution in children with pre-existing cardiovascular conditions
- • Long-term effects on adult height, cardiovascular risk, and achondroplasia-associated complications are still being characterized
What We Don't Know
Final adult height outcomes for children treated from early infancy (the expanded 2023 indication) are not yet available — those children are still growing. Whether long-term vosoritide exposure affects bone architecture, cardiovascular risk, or the incidence of achondroplasia's non-stature complications (spinal stenosis, hydrocephalus, sleep apnea) is an active area of post-marketing study. Rare long-term safety signals at scale are still accumulating, and two nonclinical gaps are worth naming plainly for a drug given daily through childhood: long-term carcinogenicity and genotoxicity studies have not been performed. No embryo-fetal toxicity was seen in rats at 14 times or rabbits at 200 times the maximum recommended dose, and no fertility effect in rats. About a third of treated children develop anti-drug antibodies, but none were neutralizing, and the label reports no link to injection-site reactions, growth response, or drug levels.
Legal Status
United States
FDA approved Voxzogo on November 19, 2021 for children with achondroplasia aged 5 years and older with open epiphyses. On October 20, 2023, the FDA expanded the indication to children of all ages with achondroplasia and open epiphyses; there is no minimum age, and the dose table starts at 3 kg. Both approvals are accelerated approvals based on growth velocity; the label itself says only that continued approval may be contingent on verification of clinical benefit in confirmatory trials, without naming adult height, though reviewers of the field describe final-height confirmation as the requirement in practice. In July 2026 the FDA accepted BioMarin's application for full approval, with a target action date of February 28, 2027, and a separate application for hypochondroplasia was filed in 2026. Voxzogo was the first targeted achondroplasia therapy in the US; once-weekly navepegritide (YUVIWEL) received accelerated approval on February 27, 2026. Access is through a manufacturer-managed specialty pharmacy with prior authorization, typically through pediatric endocrinology or clinical genetics referral.
International
Voxzogo was authorised in the EU on 26 August 2021 for ages 2 and older, and for 4 months and older since late 2023. Japan approved it in 2022 for children from birth, Australia initially for ages 2 and older, and Health Canada granted conditional approval for ages 4 months and older in early 2026, requiring a final-adult-height study report. Specific age criteria vary by country. Reimbursement and access arrangements vary by country.
Sports & Competition
Vosoritide is not named on the WADA Prohibited List. It is a pediatric therapeutic approved only in children with an active indication; it is not relevant to adult athletes. Endogenous CNP and its analogs have not been categorized as performance-enhancing for growth or recovery in adults.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Voxzogo is the only drug available for achondroplasia.
Reality
It was the first targeted therapy. Once-weekly navepegritide (YUVIWEL) was approved in the US in February 2026 for children 2 and older, oral infigratinib has positive Phase 3 data, and growth hormone has been used for achondroplasia in Japan since 1997.
Myth
Because vosoritide works in achondroplasia, it will help any short child grow taller.
Reality
It is approved only for achondroplasia, though a hypochondroplasia application is under FDA review. Trials in idiopathic short stature, Noonan syndrome, and Turner syndrome are early-stage, and hip growth-plate slips have been reported in some non-achondroplasia trial participants.
Myth
Vosoritide cures achondroplasia.
Reality
It does not correct the underlying FGFR3 mutation and does not guarantee average-stature adult height. It improves growth velocity at the growth plate by antagonizing over-active FGFR3-MAPK signaling via NPR-B–cGMP pathway activation. The gain is meaningful in a rare-disease context but partial in magnitude, and non-stature complications of achondroplasia are not eliminated.
Myth
If +1.57 cm per year is the average effect, you can simply multiply by years of treatment to predict adult height.
Reality
Growth-velocity benefit is not strictly linear across all ages and stages of growth, and individual response varies. Adult-height projections from ongoing open-label extension and real-world data are the right source for realistic estimates, not arithmetic extrapolation from a single annualized velocity.
Myth
Parents are obligated to treat a child with achondroplasia, because a drug now exists.
Reality
Whether to initiate vosoritide is a values-laden decision, and the achondroplasia community holds diverse views about medicalizing short stature. Many families, clinicians, and advocacy groups emphasize that achondroplasia is a difference rather than a deficit for many outcomes, and that the decision to treat should be individualized rather than defaulted. A skeletal-dysplasia specialist and family-centered counseling are the appropriate frame.
Myth
If it makes bones grow, it must advance bone age and close the growth plates sooner.
Reality
This is a common and reasonable parental worry, and the trials watched for it. Bone age was a monitored safety endpoint in the navepegritide pivotal trial and was tracked in the Chinese real-world cohort, and no acceleration of skeletal maturation has been reported in either. Mechanistically the drug acts on chondrocyte proliferation and differentiation within the growth plate rather than on the hormonal signals that drive epiphyseal fusion. Growth is still monitored every 3 to 6 months, and treatment stops when closure confirms no further growth potential.
Myth
A once-weekly injection is strictly better than a daily one.
Reality
For this drug class the short half-life is doing useful work. Vosoritide's only labeled warning is transient low blood pressure, and its 21-to-28-minute half-life confines that vasorelaxant effect to roughly a half-hour window after each dose, which is why the label's mitigation is simply food and fluid beforehand. A longer-acting CNP analogue spreads the same pharmacology across the week. Weekly navepegritide is approved and performs comparably on growth velocity, and BioMarin's ASPEN trial is now testing its own weekly CNP, BMN 333, head-to-head against vosoritide — but that trial does not read out until 2029, so convenience is currently a preference rather than a demonstrated advantage.
Myth
Vosoritide can make adults taller.
Reality
Therapy targets chondrocytes at open growth plates. Once epiphyses close, NPR-B-driven growth-plate activity is no longer available, and vosoritide has no mechanism to increase adult stature. It is approved and studied only in children with open growth plates.
Myth
Because Voxzogo is approved, all the long-term questions have been answered.
Reality
The pivotal Phase 3 data is robust for growth-velocity benefit over 52 weeks, with extension data out several years. Final adult height outcomes, effects on non-stature complications, and rare-event long-term safety at scale are still being characterized through post-marketing studies and patient registries.
Published Research
37 studiesAchondroplasia: Current Disease-Modifying Therapies and Genome Editing Strategies.
Retinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.
Evaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.
Emerging NPR-B agonists for cartilage and bone: from CNP biology to translational compound design.
Early closure of cranial base synchondroses in infants with Vosoritide-treated achondroplasia.
A counterweight to optimism about foramen magnum outcomes: despite early treatment the abnormal pattern of cranial base synchondrosis closure did not normalise, and three of five infants progressed to high-grade foramen magnum stenosis and underwent decompression between 8 months and 1 year 6 months of age. Five patients at a single centre, with authors disclosing BioMarin lecture fees.
Consensus statement on the management of Achondroplasia in the Middle East.
A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.
The Ethics of Growth-Promoting Pharmaceuticals for Achondroplasia.
The peer-reviewed framing of the question families actually face. Proponents emphasise potential gains in quality of life and functional independence; critics raise the pathologising of human variation, the erosion of cultural identity, and limits on a child's future autonomy. The authors conclude that ethical evaluation requires empirical evidence on both medical and quality-of-life outcomes, inclusion of disability communities in the research process, and long-term psychosocial follow-up with mandated data sharing.
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.
Perceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature: A Qualitative Study of Children and Caregivers.
Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.
Real-World Evidence on the Effectiveness and Safety of Vosoritide in Latin American Patients With Achondroplasia (EVOLAC).
Real-World Outcomes of Vosoritide Treatment in Chinese Children with Achondroplasia: The Retrospective Cohort COREV Study.
Retrospective study of foramen magnum development in patients with achondroplasia starting vosoritide before age 3.
Real-world growth outcomes and safety of vosoritide in children with achondroplasia: a Brazilian single center 24 monhts experience.
A 35-child, 24-month real-world cohort, and the source of the higher hypertrichosis figure: extra fine hair occurred in 66% of patients with no severe adverse events. Two findings matter for counselling — body proportionality was unchanged (p=0.134), and height-velocity gain during the first 12 months did not predict height-SDS gain at 24 months, so an underwhelming first year is not a reliable reason to stop.
Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.
Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs.
Evaluating the impact of vosoritide on complications of achondroplasia.
Pooled analysis (Savarirayan et al., Genet Med 2026) of 230 participants across 6 vosoritide trials reporting that the prevalence of achondroplasia complications — foramen magnum stenosis, spinal stenosis, kyphosis, hydrocephalus, leg malalignment — was consistent with or lower than untreated natural-history rates, with no evidence of complication worsening on therapy.
A phase II basket trial of vosoritide in children with RASopathies, ACAN, and NPR2 deficiency.
Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence.
The largest synthesis to date, pooling ten studies and 696 children, with an annualised growth rate 1.82 cm/year higher after treatment. Read the design carefully: this is a meta-analysis of single means, that is an uncontrolled before-and-after comparison, so the 1.82 figure is not placebo-adjusted and is not comparable to the pivotal trial's 1.57 cm/year versus placebo.
Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial.
Real-world safety and age-dependent effectiveness of vosoritide in achondroplasia: A single-center retrospective analysis of transition from growth hormone to vosoritide.
Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report.
Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
Promising horizons in achondroplasia along with the development of new drugs.
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
Randomized placebo-controlled trial in 75 children aged 3 to 59 months (30 mcg/kg under age 2, 15 mcg/kg from age 2) that supported the October 2023 US expansion to all ages with open growth plates.
Vosoritide: First Approval
Drug approval summary covering vosoritide's structural basis as a CNP analog and its approval pathway for achondroplasia.
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial
Pivotal Phase 3 trial (Savarirayan et al., Lancet 2020) establishing ~1.57 cm/year increase in annualized growth velocity with vosoritide versus placebo in children aged 5–14 with achondroplasia — the evidentiary foundation for the 2021 FDA approval.
C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia
Phase 2 dose-escalation trial establishing the growth-promoting effect of vosoritide and supporting selection of the 15 mcg/kg daily dose advanced to Phase 3.
Achondroplasia: Development, Pathogenesis, and Therapy
C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia
VOXZOGO (vosoritide) for injection — US Prescribing Information (DailyMed)
FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism (November 19, 2021)
Little People of America position statement on Voxzogo (vosoritide)
The dwarfism community's own primary statement, and the counterpoint to the clinical framing. It argues that height-related challenges stem primarily from inaccessible architecture, the absence of universal design, and societal intolerance; that research priorities should instead target spinal stenosis, sleep apnoea and the need for corrective surgery; and that it is not yet known whether improved growth velocity translates into more meaningful outcomes.
NCT07441876 — ASPEN, a Phase 2/3 study of BMN 333 versus vosoritide in children with achondroplasia
Quick Facts
- Class
- CNP Analog
- Tier
- B
- Evidence
- Strong
- Safety
- Moderate Data
- Updated
- Nov 2026
- Citations
- 37PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.